Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 756
- 主要终点
- Number of Participants With Adverse Events and Adverse Drug Reactions
研究概览
简要总结
This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular hypertension in Korea.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients treated with Ganfort® for open-angle glaucoma or ocular hypertension in clinical practice.
排除标准
- 未提供
研究组 & 干预措施
Ganfort®
Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
干预措施: bimatoprost/timolol (Drug)
结局指标
主要结局
Number of Participants With Adverse Events and Adverse Drug Reactions
时间窗: Up to 51 months
An Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. An Adverse Drug Reaction was a harmful and unintended reaction that is incurred during routine administration or use of the drug, whose causal relationship with the drug cannot be excluded.
次要结局
- Change From Baseline in Intraocular Pressure (IOP)(Baseline, Week 4)